Moderna Stock Falls After Big Covid Vaccine Writedown

Spread the love

Moderna (MRNA) swung to a loss and posted a steep drop in quarterly sales, weighed down by soft demand for its Covid-19 vaccine.

The company also forecast sales of about $4 billion for next year, softer than Wall Street analysts were expecting. Moderna said it doesn’t expect to return to organic sales growth until 2025. Chief Executive Stéphane Bancel said the company expects to break even in 2026.

During the third quarter, Moderna booked $3.1 billion in charges tied to excess Covid-19 vaccine doses and other costs, including the winding down of some manufacturing operations.

EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel210520-twitter-verified-cs-70cdee.jpg (1500×750)

Support Independent Journalism with a donation (Paypal, BTC, USDT, ETH)

News Agencies

About Author

The latest news from the News Agencies

You may also like

exotic expansion llc best stock picking services

Exotic Expansion LLC: Is it one of few Best Stock Picking Services?

Spread the loveExotic Expansion LLC: You may have wondered once in a life that if you had someone who can
investing in cryptocurrencies

Are you investing in cryptocurrencies? 4 important points before you invest

Spread the loveInvesting in cryptocurrencies Driven by financial backers’ energy, the cryptographic money market as of late crossed the $3